Thomas Bieber
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Contact Dermatitis and Allergies
- Immunology and Allergy top 0.01%
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
Papers in
- Dermatology 278
- Dermatology and Skin Diseases 249
-
- Allergic Rhinitis and Sensitization 116
- Food Allergy and Anaphylaxis Research 65
- Co-authors
- Natalija Novak (89 shared papers)Donald Y.M. Leung (5 shared papers)Joerg Wenzel (89 shared papers)Andreas Wollenberg (43 shared papers)Kenji Kabashima (11 shared papers)Jean‐Pierre Allam (31 shared papers)Lisa A. Beck (10 shared papers)Stephan Weidinger (20 shared papers)
- Journals
- Allergy (50 papers)Journal of Allergy and Clinical Immunology (42 papers)British Journal of Dermatology (30 papers)JDDG Journal der Deutschen Dermatologischen Gesellschaft (28 papers)Journal of the American Academy of Dermatology (23 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Thomas Bieber
504 papers receiving 28.2k citations
Thomas Bieber's Hit Papers
Peers
Comparison fields: 5 of 181
- Dermatology 16.8k
- Immunology and Allergy 10.1k
- Immunology 6.3k
- Rheumatology 3.5k
- Physiology 5.1k
Countries citing papers authored by Thomas Bieber
This map shows the geographic impact of Thomas Bieber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Bieber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Bieber more than expected).
Fields of papers citing papers by Thomas Bieber
This network shows the impact of papers produced by Thomas Bieber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Bieber. The network helps show where Thomas Bieber may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Bieber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 521 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003 Hit paper breakdown → | 2004 | 1683 |
| 2 | Atopic Dermatitis Hit paper breakdown → | 2008 | 1438 |
| 3 | Atopic dermatitis Hit paper breakdown → | 2018 | 1129 |
| 4 | Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis Hit paper breakdown → | 2014 | 1061 |
| 5 | Atopic dermatitis Hit paper breakdown → | 2003 | 1003 |
| 6 | Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I Hit paper breakdown → | 2018 | 835 |
| 7 | Atopic Dermatitis Hit paper breakdown → | 2010 | 482 |
| 8 | Cellular and molecular immunologic mechanisms in patients with atopic dermatitis Hit paper breakdown → | 2016 | 458 |
| 9 | A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis Hit paper breakdown → | 1997 | 419 |
| 10 | Atopic dermatitis: an expanding therapeutic pipeline for a complex disease Hit paper breakdown → | 2021 | 415 |
| 11 | 2004 | 376 | |
| 12 | 1996 | 336 | |
| 13 | Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2020 | 336 |
| 14 | 2003 | 335 | |
| 15 | Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis Hit paper breakdown → | 2021 | 310 |
| 16 | 2006 | 308 | |
| 17 | 1994 | 282 | |
| 18 | Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis Hit paper breakdown → | 2019 | 274 |
| 19 | Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 265 |
| 20 | Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) Hit paper breakdown → | 2018 | 256 |
About Thomas Bieber
Thomas Bieber is a scholar working on Dermatology, Immunology and Allergy, Immunology, Rheumatology and Physiology, having authored 521 papers that have together received 29.4k indexed citations. Recurring topics across this work include Dermatology and Skin Diseases (249 papers), Allergic Rhinitis and Sensitization (116 papers), Food Allergy and Anaphylaxis Research (65 papers), Asthma and respiratory diseases (65 papers), T-cell and B-cell Immunology (52 papers), Immunotherapy and Immune Responses (50 papers), Urticaria and Related Conditions (43 papers) and Immune Cell Function and Interaction (35 papers). The work is most often cited by research in Dermatology (16.8k citations), Immunology and Allergy (10.1k citations), Immunology (6.3k citations), Rheumatology (3.5k citations) and Physiology (5.1k citations). Thomas Bieber has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Natalija Novak, Donald Y.M. Leung, Joerg Wenzel, Andreas Wollenberg, Kenji Kabashima, Jean‐Pierre Allam, Lisa A. Beck, Stephan Weidinger, Thomas Tüting and Alan D. Irvine. Their work appears in journals such as Allergy, Journal of Allergy and Clinical Immunology, British Journal of Dermatology, JDDG Journal der Deutschen Dermatologischen Gesellschaft and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.